A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy.

Trial Profile

A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Belinostat (Primary) ; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TopoTarget
  • Most Recent Events

    • 17 Sep 2012 Subgroup analysis according to cytogenetic risk reported at the Annual Congress of the European Society for Medical Oncology (ESMO) in September 2012.
    • 03 Jul 2012 Pfizer added as associations as reported in the European Clinical Trials Database record.
    • 03 Jul 2012 Planned number of patients changed from 35 to 70 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top